SHREERAM ARADHYE
Novartis experimental actinium-based drug shows promise in prostate cancer treatment: StudyNovartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, e...
Novartis to buy experimental breast cancer drug in up to $3 billion dealSwiss drugmaker Novartis is set to acquire a promising breast cancer drug candidate from US biotech firm Synnovation Therapeutics. The deal...
Drugmakers turn to AI to speed trials, regulatory submissionsAI is helping find participants and sites for clinical trials and drafting documents for regulators, shaving weeks off these labor-intensi...
Novartis to save at least $1 bln by 2024 thanks to simplified structureThe company based in Basel appointed Marie-France Tschudin as president of innovative medicines international and chief commercial officer,...
Load More